Initiating insulin in patients with type 2 diabetes
Abstract
Overall, 7% of the US population has type 2 diabetes mellitus (T2DM), and among people aged 60 years or older, approximately 20% have T2DM, representing a significant health burden in this age group. Furthermore, the incidence of T2DM is increasing as the obesity epidemic increases and more patients are presenting with T2DM at a younger age. Insulin resistance, which is characterized by impaired glucose tolerance, begins years before the onset of T2DM. In response to impaired glucose tolerance, beta-cell function initially increases (manifested as hyperinsulinemia) to compensate for the increased insulin resistance. Subsequently, a progressive loss of first-phase insulin response occurs, which is manifested by progressively increasing postprandial glucose (PPG) levels. Fasting plasma glucose (FPG) levels eventually rise above 126 mg/dL, a level defined as clinical diabetes. As T2DM progresses, beta-cell function deteriorates further and the patient requires progressively more aggressive therapeutic interventions to achieve glycemic control. It is important for family physicians (FPs) to convey this concept of disease progression to patients at the time of diagnosis. Patients should understand that although they can slow disease progression with long-term lifestyle modifications, they will eventually need to change or add medications as the function of the pancreas continues to decline. FPs should also emphasize that disease progression can be limited but not stopped, and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.